tiprankstipranks
Adaptimmune taking back PRAME and NY-ESO target programs from GSK
The Fly

Adaptimmune taking back PRAME and NY-ESO target programs from GSK

Adaptimmune Therapeutics plc (ADAP) earlier today announced entry into a transition agreement with GSK plc (GSK) regarding the return of rights and materials comprised within the PRAME and NY-ESO cell therapy programs. Per the terms of the Agreement, Adaptimmune will receive an upfront amount plus milestone-based payments totaling GBP 30M in relation to the transfer of the clinical trials for the NY-ESO targeted programs. "The return of these T-cell programs to Adaptimmune bolsters our pipeline and our leadership position in the field of engineered TCR T-cells for solid tumors. As we have outlined in our focus areas for 2023, we are especially eager to continue development of the PRAME asset, as it is a highly expressed and validated target across a broad range of solid tumor cancers and further complements the work we have done to-date with our MAGE-A4 clinical programs. We will continue to evaluate the emerging data for the NY-ESO asset to determine next steps," said Dr. Helen Tayton-Martin, Adaptimmune’s Chief Business and Strategy Officer.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on ADAP:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles